Summary & Overview
CPT 90281: Immunoglobulin Therapy, Passive Immunity
CPT code 90281 denotes the provision of immunoglobulin, a protein used to deliver passive immunity against a range of infections. Immunoglobulin therapies are clinically important for patients with immune deficiencies, certain autoimmune conditions, and for prophylactic protection in specific exposures. Nationally, the code is relevant for payers, providers, and infusion centers that manage and bill for parenteral immunoglobulin products.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for immunoglobulin use, common billing and service settings, and the types of benchmarks and policy topics typically associated with specialty biologic and infusion therapies. The publication outlines typical sites of service where CPT code 90281 is billed and explains the role of this code within broader immunoglobulin utilization and coverage discussions.
The content is intended to inform billing staff, revenue cycle managers, and policy analysts about the clinical purpose of the code, payer coverage landscape, and areas where payers commonly apply utilization controls or prior authorization for immunoglobulin therapies. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 90281 describes immunoglobulin, a complex protein produced by certain immune cells that provides passive immunity against infections. The service represented by this code is the provision of immunoglobulin preparations for therapeutic or prophylactic use.
-
Service type: Therapeutic immunoglobulin product administration
-
Typical site of service: Infusion center, hospital outpatient department, or clinic setting where parenteral immunoglobulin is prepared and administered
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric patient with primary or secondary immunodeficiency, autoimmune disease requiring passive immunotherapy, or recurrent severe infections who receives immunoglobulin therapy to provide passive immunity. The clinical workflow begins with an order from an immunologist, neurologist, hematologist, or primary care provider documenting the indication and dose. Verification of patient identity, allergies, and baseline vital signs occurs in an infusion center, hospital outpatient infusion clinic, physician office-based infusion suite, or home infusion setting. Pre-infusion assessment includes review of prior reactions, current medications, and laboratory data (e.g., immunoglobulin levels, renal function). The product is prepared according to manufacturer instructions and institutional policies, administered intravenously or subcutaneously by trained nursing staff, and monitored for infusion-related adverse events (e.g., infusion reactions, anaphylaxis, renal dysfunction, thromboembolic events). Post-infusion documentation includes dose, lot numbers, infusion rate adjustments, patient tolerance, and discharge instructions. Billing captures the immunoglobulin product administration and any applicable facility, professional, or supply components using the appropriate CPT and modifier codes for the service location and circumstances.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default/No modifier | Use when no specific modifier applies to the service. |